Companies / Health Care
IQV
IQVIA
Life Sciences Tools & Services
Life Sciences Tools & ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health56
Growth42
Profitability45
Cash generation75
Balance sheet17
Dilution control99
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)8.0%Revenue growth (FY)5.9%Revenue CAGR (3y)4.2%Gross margin—Operating margin13.4%Net margin8.3%Free cash flow margin12.6%R&D / revenue—Stock comp / revenue1.5%Net debt / operating cash flow5.18xCurrent ratio0.75Diluted share count change-5.4%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $13.9B | $14.4B | $15.0B | $15.4B | $16.3B |
| Operating income | $1.4B | $1.8B | $2.0B | $2.2B | $2.2B |
| Net income | $966M | $1.1B | $1.4B | $1.4B | $1.4B |
| Operating cash flow | $2.9B | $2.3B | $2.1B | $2.7B | $2.7B |
| Capital expenditure | $640M | $674M | $649M | $602M | $603M |
| Free cash flow | $2.3B | $1.6B | $1.5B | $2.1B | $2.1B |
| Stock-based comp | $170M | $194M | $217M | $206M | $247M |
| Buybacks | $406M | $1.2B | $992M | $1.4B | $1.2B |
| Cash | $1.4B | $1.2B | $1.4B | $1.7B | $2.0B |
| Total debt | $12.1B | $12.7B | $13.7B | $14.0B | $15.7B |
| Equity | $6.0B | $5.8B | $6.1B | $6.1B | $6.5B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.